Introduction: Deep venous thrombosis (DVT) is considered a preventable complication in trauma patients. Hospitals risk financial penalties for DVT rates above accepted benchmarks. These penalties do not apply to chronic DVT which develop prior to admission. Lower-extremity duplex ultrasound (LEDUS) can detect characteristics of thrombus chronicity, allowing differentiation of chronic from acute DVT. The objective of this study was to determine the prevalence of chronic DVT in hospitalized trauma patients. Methods: We performed a retrospective review of trauma patients admitted to our Level I trauma center between 7/1/2006 and 10/30/2016 who had a DVT on initial screening LEDUS. Our center utilizes screening and surveillance LEDUS for patients admitted > 48 hours. Definitions for chronic and acute DVT were extracted from existing literature. Patients with DVT on initial LEDUS underwent review of that LEDUS to assess clot chronicity and were classified as having acute DVT, chronic DVT, or DVT of indeterminate age. Demographic data, medical history, and injury characteristics were collected. Patients with acute DVT and chronic DVT were compared. Results: The prevalence of chronic DVT among patients with a DVT on initial LEDUS was 29.9%. Chronic DVT occurred in patients who were older and less-severely injured. An above-knee component was significantly more common in chronic DVT (65%). Only 34 (41%) of those with chronic DVT reported a history of DVT. Among patients with chronic DVT, 44 (53%) had a subsequent LEDUS, of whom 4 (9%) showed thrombus progression and 6 (14%) formed a new DVT. Conclusion: LEDUS can identify chronic DVT, which represents nearly 30% of all DVT found on initial screening LEDUS in trauma patients. Those with chronic DVT should receive pharmacologic and mechanical prophylaxis because of the incidence of progression and new acute DVT. They should also be counseled regarding the possibilities of recurrence and chronic venous insufficiency. Level of Evidence: Level III, diagnostic study (C) 2017 Lippincott Williams & Wilkins, Inc.
from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2exoOAZ
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Ph...
-
http://bit.ly/2TO0eLw
-
Training in teamwork behaviour improves technical resuscitation performance. However, its effect on patient outcome is less clear, partly be...
-
Abstract Objective Long-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms...
-
Medicine by Alexandros G. Sfakianakis BioMed Research International BioMed Research InternationalTanshinone IIA Alleviates CCL2-Induced Le...
-
Abstract Chronic venous disease (CVD) is both prevalent and unavoidable in many people as a result of persistent or unalterable risk facto...
-
Abstract Chronic low-grade inflammation is now widely accepted as one of the most important contributors to metabolic disorders. Glycoprot...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου